Clinical efficacy and safety of the ealry intervention with Tolvaptan(V2 receptorinhibiter)in hospitalized patients with acute exacerbation of chronic heart failur:A randomized open-labeled parallel controlled study

Phase 2

• Conditions: Acute exacerbation of chronic heart failure

• Registration Number: JPRN-UMIN000012716
• Lead Sponsor: JI-TOKUSHUKAI MEDICAL CENTER Cardiovascular Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-12-27
• Study Completion: 2016-12-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1 Patients with a history of hypersensitivity for an ingredient of tolvaptan or analogues such as Mozavaptan. 2 Patients with lowering consciousness. 3 Patients who need treatment with respirator. 4 Patients who receive artificial dialysis. 5 Patients with anuria. 6 Patients with severe liver disfunction. 7 Patients who cannot feel thirst or are difficult to intake the fluid. 8 Patients with hypernatremia. 9 Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant. 10 Patients otherwise judged by the investigator or sub-investigator to be inappropriate for inclusion in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified